TheraRadar
← Back
Data updated: May 24, 2026

GENPHARM

Generics
OncologyCardiovascularOphthalmology

GENPHARM is a generic drug manufacturer focused on Oncology, Cardiovascular, Ophthalmology.

1997
Since
4
Drugs
-
Trials
0
New Drugs (2yr)

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

No active drugs

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

No recent approvals

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Oncology 60%
0 drugs Phase 3: 11 Phase 2: 3 Phase 1: 5
Cardiovascular 15%
2 drugs Phase 2: 1
Ophthalmology 15%
0 drugs Phase 3: 3 Phase 2: 1
Infectious Disease 7%
0 drugs Phase 3: 1 Phase 1: 2
Respiratory 2%
0 drugs Phase 2: 1

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

15
Phase 3
6
Phase 2
7
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling